LIFECORE BIOMEDICAL, INC. \DE\

LFCR

Explore Our Financial Data > Companies > Santa Clara, Minnesota Companies > LIFECORE BIOMEDICAL, INC. \DE\
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
LFCR
CIK0001005286
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address3515 LYMAN BOULEVARD, CHASKA, MN, 55318
Website www.landec.com
Phone9523684300
CEOJames G. Hall
Employees690

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$135.27 million
Pre-Tax Income$-32.08 million
Net Income$-32.48 million
Net Income to Common$-39.04 million
EPS$-1.03
View All
Balance Sheet
Cash$18.86 million
Assets$235.20 million
Liabilities$198.42 million
Common Equity$-10.54 million
Liabilities & Equity$235.20 million
View All
Cash Flow Statement
Net Income$-32.48 million
Cash From Operating Activities$2.17 million
Cash From Investing Activities$-4.73 million
Cash From Financing Activities$3.94 million
Change in Cash$1.38 million
View All
Calculations
NOPAT$-6.11 million
EBITDA$-1.27 million
Price to EarningsN/A
Price to BookN/A
ROE-85.14%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Lifecore Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”) a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that effective on March 25, 2026, Lifecore granted a restricted stock unit (“RSU”) award with respect to 18,500 shares of its common stock under Lifecore’s Equity Inducement Plan, as amended (the “Inducement Plan”) to a newly hired employee of Lifecore. The RSU award was granted pursuan

Article Link

Lifecore Biomedical Signs Two New Agreements with Existing U.S. Biopharmaceutical Customer

-- Site Transfer Agreement for the Manufacture of Commercially Marketed Product -- -- Second Agreement Supports the Expansion of Product Commercially Manufactured at Lifecore to a New Delivery System -- -- Fourth Commercial Site Transfer Agreement Win in Five Months -- -- Both Programs are Additive to Lifecore’s High-Value, Late-Stage Pipeline and Expected to Contribute to 2028 Commercial Revenue -- CHASKA, Minn., March 26, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Life

Article Link

Lifecore Biomedical Signs Commercial Site Transfer Agreement with Leading Medical Aesthetics Company

-- Agreement for the Commercial Manufacture of Established, Approved Aesthetic Product -- -- Third Commercial Site Transfer Agreement Win in Five Months -- -- Program Expected to Generate Commercial Revenue in 24 Months, Contributing to 2029 Revenue CAGR -- CHASKA, Minn., March 23, 2026 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated injectables contract development and manufacturing organization (“CDMO”), today announced that it has signed a CDMO ma

Article Link

Lifecore Biomedical CEO: Standalone CDMO Shift Complete, Utilization to Hit 60% by 2029

Lifecore Biomedical (NASDAQ:LFCR) CEO Paul Josephs told investors at a KeyBanc conference that the company has completed its transition into a “standalone CDMO” after divesting its former food businesses in 2022 and 2023. Josephs said Lifecore is now focused on two primary operations at its single s

Article Link

Lifecore Biomedical Inc (LFCR) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ...

Lifecore Biomedical Inc (LFCR) reports a 10% revenue increase in Q4 2025 and outlines strategic initiatives to drive future growth despite anticipated challenges.

Article Link